Alnylam Pharmace. buy BMO Capital Markets
Summary
This prediction ended on 25.06.25 with a price of €278.20. The BUY prediction by BMO_Capital_Markets for Alnylam Pharmace. saw massive gains of 32.04%. BMO_Capital_Markets has a follow-up prediction for Alnylam Pharmace. where he still thinks Alnylam Pharmace. is a Buy. BMO_Capital_Markets has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Alnylam Pharmace. | 1.745% | 1.745% | 22.960% |
| iShares Core DAX® | -1.673% | 2.237% | 16.344% |
| iShares Nasdaq 100 | -1.346% | 0.290% | 3.851% |
| iShares Nikkei 225® | -1.529% | 5.863% | 18.286% |
| iShares S&P 500 | -1.702% | 0.697% | 1.755% |
Comments by BMO_Capital_Markets for this prediction
In the thread Alnylam Pharmace. diskutieren
In the thread Trading Alnylam Pharmace.
Current prediction by BMO_Capital_Markets for Alnylam Pharmace.
Stopped prediction by BMO_Capital_Markets for Alnylam Pharmace.
Alnylam Pharmace.
05.09.25
05.09.26
16:00
Alnylam Pharmace.
27.03.24
27.03.25
28.03.25

